NCT00648102View on ClinicalTrials.gov

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

December 31, 2009

Conditions
Breast CancerColorectal CancerPancreatic CancerBladder CancerOvarian Cancer
Interventions
BIOLOGICAL

CDX-1307

Trial Locations (3)

27710

Duke University, Durham

28078

Carolina BioOncology Institute, Huntersville

48202

Henry Ford Health System, Detroit

Sponsors
All Listed Sponsors
lead

Celldex Therapeutics

INDUSTRY

NCT00648102 - Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | Biotech Hunter | Biotech Hunter